GenNext Technologies
GenNext Technologies offers Hydroxyl Radical Protein Footprinting (HRPF) products and services, including the Fox® and AutoFox® Protein Footprinting Systems, to pharmaceutical researchers.
Services
GenNext Technologies provides Hydroxyl Radical Protein Footprinting (HRPF) products and services to pharmaceutical researchers. Their expertise centers on delivering in-solution structure and interaction information for a diverse range of protein sizes, states, and concentrations. GenNext Technologies offers full-solution biopharmaceutical protein footprinting services in collaboration with Emery Pharma, enhancing their ability to support complex protein studies.
Products
GenNext Technologies offers several key products in the HRPF domain. The Fox® Protein Footprinting System is a benchtop instrument that utilizes hydroxyl radicals to examine amino acid side chain solvent accessibility. Accompanied by the intuitive FoxWare® Software, it aids in efficient data processing. The AutoFox® Protein Footprinting System advances this technology by enabling fully-automated, laser-free protein footprinting. It features a plug-and-play opto-fluidic chip for reagent mixing, photolysis, and dosimetry measurements. These products cater to applications such as drug-binding, mAb therapeutics, protein aggregation, and formulation studies.
Technology
GenNext Technologies' HRPF technology is designed to deliver dynamic and detailed protein structure information under physiological conditions. The Fox System's performance is comparable to beam line x-ray synchrotron radiation, ensuring precise results for radical protein footprinting experiments. The user-friendly design and fully automated features in the AutoFox® System allow for rapid sample labeling and processing. With the use of hydroxyl radicals, this technology offers an advanced alternative to traditional, hazardous laser-based methods.
Industry Collaboration
GenNext Technologies has established several significant partnerships to advance their HRPF technology. A notable collaboration with SCIEX aims to co-market an advanced higher-order structure (HOS) workflow for biopharmaceutical research. Additionally, a distribution agreement with Worldwide Technology extends their reach to the People's Republic of China, facilitating broader access to their innovative products. These collaborations emphasize GenNext Technologies' commitment to expanding their impact in the biopharmaceutical industry.
Funding
GenNext Technologies has secured nearly $7M in NIH grant awards to support the development of their HRPF technology. These funds have been instrumental in advancing their research and product offerings, reinforcing their role as a key player in the pharmaceutical research sector. The financial support from NIH underscores the relevance and potential of their innovative solutions in addressing complex protein analysis challenges.